A growing pipeline of RNA-based cancer diagnostics

Pipeline Focus: Commercially Available PurISTSM Pancreatic Cancer Test

By applying cancer subtyping with the rT(I)ME Explorer Platform to specific types of cancer and target biology, our diagnostics pipeline is actively engaged in deriving drug-predictive response signatures and companion diagnostics for targeted therapies and immunotherapies.

Many tumor types share common molecular subtypes, allowing us to leverage these characteristic subtypes to identify candidate responder populations across indications. We work with nearly any mechanism of action and have the capability to build de novo gene signatures for select pharmaceutical partners.